Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years
The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...
Novo Nordisk to Pay Up to $2 Billion for Rights to Experimental Obesity and Diabetes Drug
Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...
PharmExec2d
Rybelsus Found to Significantly Reduce Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes, Cardiovascular Disease
In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...
Novo Nordisk Raises Awareness of Chronic Kidney Disease & Type 2 Diabetes Treatment Option, Ozempic®
March is National Kidney Month – a time to raise awareness and learn more about kidney health and kidney disease. Earlier in ...
NBC New York6d
Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years
which is already approved for Type 2 diabetes, at the American College of Cardiology's Annual Scientific Session in Chicago. Novo Nordisk has already applied in the U.S. and EU to expand the ...